Description
PNC-27 Technical Overview
PNC-27 is an experimental chimeric peptide developed from a segment of the p53 tumor suppressor protein and a membrane-associated peptide sequence. Its design incorporates an HDM2-binding region derived from p53 and a membrane residency component.
PNC-27 has been investigated in laboratory research involving membrane-associated HDM2, peptide-protein interactions, and the integrity of plasma membranes in cancer cell models.
Experimental investigations have reported that PNC-27 can interact with HDM2-associated membrane structures and induce pore formation in certain malignant cell lines. These findings remain preclinical and do not establish clinical safety, cancer selectivity, or therapeutic efficacy.
Compound Specifications
| Property | Value |
|---|---|
| Compound Name | PNC-27 |
| Compound Classification | Synthetic chimeric research peptide |
| Structural Origin | p53-derived HDM2-binding region |
| Research Target | Membrane-associated HDM2 |
| Peptide Structure | p53-derived segment linked to a membrane residency peptide |
| Complete Sequence | Requires confirmation against the manufacturer’s structural documentation |
| Molecular Formula | Requires structural verification |
| Molecular Weight | Requires structural verification |
| Source | Synthetic |
| Vial Content | 10mg |
| Research Category | Experimental Oncology Research |
The product’s complete chemical identity, including terminal modifications and counterions, must be confirmed through analytical documentation.
Storage and Handling
- Store according to manufacturer-validated stability conditions.
- Protect the research material from moisture and unnecessary light exposure.
- Keep containers securely sealed.
- Avoid unnecessary temperature fluctuations.
- Follow laboratory procedures appropriate for experimental cytotoxic compounds.
Lyophilized Format
PNC-27 may be supplied as a lyophilized synthetic peptide. The physical form, excipients, and formulation-specific stability must be verified against documentation for the supplied batch.
Research Use Disclaimer
PNC-27 is an experimental research compound and is not an FDA-approved cancer treatment. It is not intended for human or veterinary administration, diagnostic procedures, or therapeutic use. Published experimental findings do not establish safety or efficacy in humans.
Frequently Asked Questions
What Is PNC-27 10mg?
PNC-27 10mg is a research preparation of a synthetic chimeric peptide designed around the HDM2-binding region of p53.
What Is the Research Target of PNC-27?
Studies have investigated interactions between PNC-27 and HDM2 associated with the plasma membranes of certain cancer cells.
How Does PNC-27 Differ From PNC-28?
PNC-27 and PNC-28 are related but distinct experimental constructs derived from different p53-related sequences.
What Research Areas Involve PNC-27?
Research areas include HDM2 interactions, membrane pore formation, peptide engineering, and experimental cancer cell biology.
Is PNC-27 Approved for Human Use?
No. PNC-27 is not FDA-approved for therapeutic use.
Research Overview
PNC-27 was developed as part of research exploring whether a p53-derived peptide could be directed toward membrane-associated molecular targets. Its experimental design combines a p53-related HDM2-binding sequence with a membrane-associated segment.
Laboratory investigations have examined membrane disruption, cellular viability, and protein interactions following exposure to PNC-27.
HDM2 Interaction Research
HDM2 is a regulatory protein involved in controlling p53 activity. PNC-27 research has examined the significance of HDM2 localization at the surface of selected malignant cells.
Membrane Pore Formation Research
Experimental studies have reported membrane pore formation and loss of membrane integrity in certain cancer cell models exposed to PNC-27.
The observed responses depend on the biological model and experimental conditions.
Cellular Viability Research
Researchers have investigated PNC-27-associated changes in cell survival and membrane permeability. These observations do not establish selective or safe elimination of malignant cells in humans.
Research Applications
| Research Area | In Vitro Application |
|---|---|
| HDM2 Research | Protein localization and interaction assays |
| Membrane Biology | Membrane permeability and pore formation studies |
| Peptide Engineering | Investigation of chimeric peptide structures |
| Experimental Oncology | Cellular viability assays in defined cancer cell models |
References
- PNC-27 and HDM2 Interaction Research. PubMed PMID: 20080680.
- PNC-27 Experimental Research. Biomedicines, 2022, 10(5), 945.
Certificate of Analysis (COA)
Analytical documentation should confirm the peptide’s complete sequence, molecular identity, purity, and actual content. A chromatographic purity measurement alone does not establish the identity of a particular chimeric peptide construct.
For available batch documentation, contact Peptide Lives.
Reviews
There are no reviews yet.